Clinical Laboratory Improvement Advisory Committee (CLIAC); Correction, 49110-49111 [2019-20180]
Download as PDF
<![CDATA[
49110
Federal Register / Vol. 84, No. 181 / Wednesday, September 18, 2019 / Notices
dnpao/state-local-programs/reach/
index.htm or https://
www.challenge.gov. On these sites,
applicants will find the guidelines for
participating. Applying will require
applicants to provide a free-text written
statement of 500 words or less that
describes the unique and innovative
approach that led to reduced health
disparities in chronic disease.
khammond on DSKJM1Z7X2PROD with NOTICES
Amount of the Prize
A maximum of one (1) Applicant
(individual or team) will receive a
plaque (‘‘Winner’’). While the winner
may be invited to meetings by CDC or
non-federal individuals/organizations
from outside the agency, attendance at
such events is not required as a
condition of accepting the Prize. No
cash prize will be awarded. The selected
applicant will receive a plaque and
recognition.
Basis Upon Which Winner Will Be
Selected
CDC- or non-federal individuals from
outside the agency will facilitate a panel
of three to five experts consisting of
CDC staff and other national experts to
review the applications and select a
winning entry from all eligible entries
based on the following judging criteria:
• The extent to which the applicant’s
work shows alignment with CDC Office
of Minority Health and Health Equity
(OMHHE) health equity goals to
decrease health disparities, address
social determinants of health, and
promote access to high quality
preventive healthcare. (20 points)
• The extent to which the applicant’s
work addressed health issues, including
hypertension, heart disease, Type 2
diabetes, and/or obesity, and/or
addressed the following preventable risk
behaviors: Tobacco use, poor nutrition,
or physical inactivity. (20 points)
• The extent to which the applicant’s
work demonstrated success in systems
improvement that impacted health
outcomes in one or more of the
following areas: Access to quality care,
education, employment, income,
community environment, housing, and
public safety. (20 points)
• The extent to which the applicant’s
work provided a unique or innovative
solution to improving outcomes for
groups most affected by health
disparities, specifically, African
Americans/Blacks, American Indians/
Alaska Natives, Asian Americans,
Hispanic Americans, and Native
Hawaiian/Pacific Islanders. (20 points)
• The extent to which the applicant
engaged members of the community
across different sectors and successfully
demonstrated the development and/or
VerDate Sep<11>2014
19:01 Sep 17, 2019
Jkt 247001
implementation and/or evaluation of the
work within the community related to
groups most affected by health
disparities. (20 points)
Judges will use a point system out of
100 to select the winner putting equal
emphasis on the bases discussed above.
In addition to the 500 word or less freetext written statement, applicants can
also submit evidence that demonstrates
that the criteria were met through
publications, links to online content,
and other forms of written material.
After the selection process has been
completed, up to 9 applicants (inclusive
of the winner) may be asked to
participate in a post-challenge
telephone discussion about the
interventions used by the individual or
team to successfully promote health
equity and reduce health disparities.
Themes from these discussions may be
shared publicly to provide additional
information to promote innovative and
unique interventions that led to reduced
health disparities.
Additional Information
The challenge website may post the
number of applications received but
will not include confidential or
proprietary information about
individual applicants. The information
submitted by applicants will not be
posted on the website. Information
collected from applicants will include
general details, such as the business
name, address, and contact information
of the nominee. This type of information
is generally publicly available.
Information for the Winner, such as
the name of the individual or team,
location, priority population, and health
outcomes will be shared through press
releases, the challenge website, and
Division of Nutrition, Physical Activity,
and Obesity and CDC Resources. Details
regarding the Winner and its application
may be shared with the public as part
of a success story.
The award is named in honor of Lark
Galloway-Gilliam, the founding
Executive Director of Community
Health Councils, Inc. (CHC). CHC began
in 1992 to support planning, resource
development, and policy education in
response to the growing health crisis in
the South Los Angeles area and other
under-resourced and marginalized
communities throughout LA County.
Lark led the CHC team to engage
communities and strengthen the
connections among organizations in
order to improve health, eliminate
disparities, and achieve health equity.
Under Lark’s leadership, CHC became
an expert in health equity in Los
Angeles, across California, and the
country. Lark also served in several
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
leadership roles, including the first
president of the National REACH
Coalition, the MLK Medical center
Advisory Board, and the IP3 Board of
Directors for Community Commons.
Compliance With Rules and Contacting
Challenge Winners
Applicants and the Challenge Winner
(and all members of the team, if a team
is selected as the Winner) must comply
with all terms and conditions of these
Official Rules, and winning is
contingent upon fulfilling all
requirements herein. The Winner will
be notified by email, telephone, or mail
after the date of the judging.
Privacy
If applicants choose to provide HHS/
CDC with personal information by
registering or filling out the submission
form through the Challenge.gov website,
that information is used to respond to
Contestants in matters regarding their
submission, announcements of entrants,
finalists, and winners of the Contest.
Information is not collected for
commercial marketing. Winners are
permitted to cite that they won this
contest.
General Conditions
HHS/CDC reserves the right to cancel,
suspend, and/or modify the Challenge,
or any part of it, for any reason, at HHS/
CDC’s sole discretion.
Participation in this Challenge
constitutes an applicants’ full and
unconditional agreement to abide by the
Challenge’s Official Rules found at
www.Challenge.gov.
Authority: 15 U.S.C. 3719.
Dated: September 12, 2019.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2019–20162 Filed 9–17–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee (CLIAC);
Correction
Notice is hereby given of a change in
the meeting of the Clinical Laboratory
Improvement Advisory Committee
(CLIAC); November 6, 2019, 8:30 a.m. to
5:00 p.m., EST and November 7, 2019,
8:30 a.m. to 12:00 p.m., EST which was
published in the Federal Register on
E:\FR\FM\18SEN1.SGM
18SEN1
Federal Register / Vol. 84, No. 181 / Wednesday, September 18, 2019 / Notices
August 30, 2019, Volume 84, Number
169, pages 45765–45766.
The MATTERS TO BE CONSIDERED
should read as follows: The agenda will
include agency updates from CDC, the
Centers for Medicare and Medicaid
Services (CMS); and the Food and Drug
Administration (FDA). Presentations
and discussions will focus on a follow
up on CLIAC recommendations; an
update on the clinical laboratory
workforce; improving integration of
laboratory information systems with
electronic health records; and future
CLIAC topics. There will be an extended
public comment session focusing on
emerging technologies and the clinical
laboratory. Agenda items are subject to
change as priorities dictate.
FOR FURTHER INFORMATION CONTACT:
Nancy Anderson, MMSc, MT(ASCP),
Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop V24–3,
Atlanta, Georgia 30329–4027, telephone
(404) 498–2741; NAnderson@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2019–20180 Filed 9–17–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–4187]
A New Era of Smarter Food Safety;
Public Meeting, Request for Comments
khammond on DSKJM1Z7X2PROD with NOTICES
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug
Administration (FDA, the Agency, or
we) is announcing the following public
meeting entitled ‘‘A New Era of Smarter
Food Safety’’ to get input from a broad
SUMMARY:
VerDate Sep<11>2014
19:01 Sep 17, 2019
Jkt 247001
cross-section of stakeholders on a
modern approach the Agency is taking
to strengthen its protection of the food
supply. The purpose of this meeting is
to foster a dialogue with our domestic
and international regulatory and public
health partners, industry, consumers,
academia, and others. The input
received at this meeting, and in
comments submitted to the docket, will
be used to shape an FDA Blueprint for
a New Era of Smarter Food Safety. This
Blueprint will outline how this modern
approach will address public health
challenges, ranging from being able to
trace sources of contaminated foods, to
using new predictive analytics tools like
artificial intelligence to assess risks, and
help prioritize the Agency’s work and
resources.
DATES: The public meeting will be held
on October 21, 2019, from 8:30 a.m. to
5 p.m. Submit either electronic or
written comments on this public
meeting by November 20, 2019. See the
SUPPLEMENTARY INFORMATION section for
registration date and information.
ADDRESSES: The public meeting will be
held at the Hilton Washington DC/
Rockville Hotel and Executive Meeting
Center, 1750 Rockville Pike, Rockville,
MD 20852. For more information on the
hotel see https://www.fda.gov/food/
news-events-cfsan/workshops-meetingswebinars-food-and-dietary-supplements.
You may submit comments as
follows. Please note that late, untimely
filed comments will not be considered.
Electronic comments must be submitted
on or before November 20, 2019. The
https://www.regulations.gov electronic
filing system will accept comments
until 11:59 p.m. Eastern Time at the end
of November 20, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
49111
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No.FDA–2019–
N–4187 for ‘‘A New Era of Smarter Food
Safety.’’ Received comments, those filed
in a timely manner (see ADDRESSES),
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
E:\FR\FM\18SEN1.SGM
18SEN1
]]>Agencies
[Federal Register Volume 84, Number 181 (Wednesday, September 18, 2019)]
[Notices]
[Pages 49110-49111]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-20180]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC);
Correction
Notice is hereby given of a change in the meeting of the Clinical
Laboratory Improvement Advisory Committee (CLIAC); November 6, 2019,
8:30 a.m. to 5:00 p.m., EST and November 7, 2019, 8:30 a.m. to 12:00
p.m., EST which was published in the Federal Register on
[[Page 49111]]
August 30, 2019, Volume 84, Number 169, pages 45765-45766.
The MATTERS TO BE CONSIDERED should read as follows: The agenda
will include agency updates from CDC, the Centers for Medicare and
Medicaid Services (CMS); and the Food and Drug Administration (FDA).
Presentations and discussions will focus on a follow up on CLIAC
recommendations; an update on the clinical laboratory workforce;
improving integration of laboratory information systems with electronic
health records; and future CLIAC topics. There will be an extended
public comment session focusing on emerging technologies and the
clinical laboratory. Agenda items are subject to change as priorities
dictate.
FOR FURTHER INFORMATION CONTACT: Nancy Anderson, MMSc, MT(ASCP), Senior
Advisor for Clinical Laboratories, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia
30329-4027, telephone (404) 498-2741; [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-20180 Filed 9-17-19; 8:45 am]
BILLING CODE 4163-18-P
